Compare GPRE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 778.3M |
| IPO Year | 2004 | 2007 |
| Metric | GPRE | EVO |
|---|---|---|
| Price | $16.17 | $1.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $12.57 | $7.00 |
| AVG Volume (30 Days) | ★ 1.2M | 45.9K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $11.85 | $10.05 |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.54 | $1.90 |
| 52 Week High | $19.65 | $4.27 |
| Indicator | GPRE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 35.64 |
| Support Level | $13.95 | N/A |
| Resistance Level | $16.69 | $3.84 |
| Average True Range (ATR) | 0.76 | 0.05 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 51.15 | 0.97 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.